Our findings provide critical insight into the association of MKRN2 expression with favorable clinicopathological characteristics in NSCLC patients and suggested that MKRN2 plays a role in inhibiting NSCLC development. This evidence concerns the gene MKRN2 and non-small cell lung carcinoma.